news
Inexpensive drug protects against COVID-19 inflammation in pre-clinical trials
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
List view / Grid view
Hit-to-Lead
article
COVID-19 drug targets and cell-based assays
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
news
Aptamer inhibits SARS-CoV-2 with novel mechanism of action, study shows
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
whitepaper
Whitepaper: Simple Western™ produces publication-ready results
Simple Western™ is an automated capillary immunoassay that produces publication-ready data to meet the highest standards of data integrity and rigor.
whitepaper
Catalogue: Nuclease-Free tubes, tips & buffers
Working with RNA requires rigorous nuclease contamination controls in place. Stock up on Nuclease-Free tubes tips and buffers #Back2Lab
news
Antisense oligonucleotide with potential to combat COVID-19 developed
Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.
whitepaper
Catalogue: Ribosomal RNA from bacteria with RiboMinus
RiboMinus Bacteria 2.0 Transcriptome Isolation Kits perform efficient transcriptome enrichment from total bacterial RNA. Improve your RNA extraction from bacteria today.
news
Potential peptide to treat multiple sclerosis passes toxicology test
A peptide that could treat multiple sclerosis caused no neurotoxicity or cardiotoxic effects in zebrafish, a study has shown.
news
New inhibitor found to combat drug-resistant cancer cells
A team has developed a novel inhibitor that blocks a protein in cancer cells, making drug-resistant tumours respond to chemotherapy.
article
Developing bioenergetic nanocatalysts, a novel approach to treat neurodegeneration
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
news
Reversible male contraceptive shows promise in pre-clinical studies
Researchers have discovered the the compound triptonide is safe, effective and reversible as a male contraceptive in animal models.
news
Compounds that inhibit main protease of SARS-CoV-2 discovered
Using high-throughput screening techniques, researchers have identified two families of active substances that block SARS-CoV-2 replication.
webinar
Paradigm Shift in Drug Discovery: Discover Small Molecule Degraders Using E3scan™ Technology Platform
4 March 2021 | By Eurofins Discovery
Book your place for our free webinar and learn about how targeted protein degradation (TPD) utilises small molecules to hijack the cellular degradation machinery through the recruitment of E3 ubiquitin ligases to proteins of interest.
whitepaper
Article: Tackling the challenges of limited resources during a pandemic
As laboratories face the challenge of screening many samples for SARS-CoV-2, lab managers have turned to the use of automation to address key concerns.
news
New drug shows potential as prophylactic for Alzheimer’s disease
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
